MRK•November 17, 2026 at 9:15 PM UTCPharmaceuticals, Biotechnology & Life Sciences

Merck Discontinues Nemtabrutinib Program in Hematologic Cancers

Read source article

What happened

Merck announced the discontinuation of the clinical development program for nemtabrutinib (MK-1026), an investigational oral BTK inhibitor being evaluated in chronic lymphocytic leukemia, small lymphocytic leukemia, and other hematologic malignancies under the BELLWAVE program. The decision removes one mid-stage pipeline asset from Merck's oncology portfolio, which remains heavily dependent on Keytruda for near-term revenue. While nemtabrutinib was not a top-line driver in the company's post-Keytruda diversification strategy, its failure underscores the inherent risk in replacing a blockbuster franchise. Merck's broader transition plan relies on large-scale business development, recent acquisitions, and cost restructuring rather than this single asset, so the financial impact is likely minimal. Investors should view this as a routine pipeline pruning in a crowded BTK inhibitor space, where multiple competitors already have approved therapies.

Implication

For investors, the discontinuation of nemtabrutinib removes a modest optionality from the pipeline but does not materially change the investment thesis. The core challenges remain Keytruda's eventual loss of exclusivity and the unresolved Gardasil China situation, which dominate the risk profile. This event highlights the execution risk in Merck's pipeline, but the company has ample financial capacity to absorb such failures and continue its acquisition-driven diversification. The WAIT rating remains appropriate, with key catalysts being China shipment resumption and successful integration of recent deals. Long-term value hinges on whether Merck can build non-Keytruda revenue pillars before 2028-2029, and today's news is a reminder that not every pipeline bet will pay off.

Thesis delta

The prior thesis emphasized Merck's reliance on Keytruda and the need for diversification through acquisitions and new launches, with nemtabrutinib not a central pillar. Its discontinuation slightly reduces pipeline breadth but does not alter the fundamental economics or the timing of Keytruda and Gardasil pressures. The thesis remains unchanged: Merck is in a holding pattern, and investors should focus on larger strategic moves rather than this early-stage asset.

Confidence

medium